Study on Trace Amine-associated Receptor 1 (TAAR1) Ligand Neuron, D-neuron

Authors

  • Keiko Ikemoto Department of Psychiatry, Iwaki City Medical Center, Iwaki, Japan.

DOI:

https://doi.org/10.9734/bpi/rdmmr/v4/13668D

Keywords:

Dopamine, medicinal chemistry, TAAR1, psychosis

Abstract

The latest psychopharmacological study showed effectiveness of a novel non-D2-receptor-binding drug, SEP-363856, for the treatment of schizophrenia. The compound is trace amine-associated receptor 1 (TAAR1) full agonist and also 5-hydroxytryptamin 1A (5-HT 1A) receptor partial agonist. I found the TAAR1 ligand neuron, D-neuron, in the striatum and nucleus accumbens (Acc), a neuroleptic acting site, of human brain, though failed to find in the homologous area of monkey brain. To study human D-neuron functions, total of 154 post-mortem brains, and a modified immunohistochemical method using high qualified antibodies against monoamine-related substances, was applied. The number of D-neuron in the caudate nucleus, putamen, and Acc was reduced in post-mortem brains with schizophrenia. The reduction was significant (p<0.05) in Acc. I proposed “D-cell hypothesis of schizophrenia”, that NSC dysfunction-based D-neuron reduction is cellular and molecular basis of mesolimbic dopamine (DA) hyperactivity, progressive pathophysiology and prospectiveness of TAAR1 medicinal chemistry.

Published

2021-10-04

How to Cite

Keiko Ikemoto. (2021). Study on Trace Amine-associated Receptor 1 (TAAR1) Ligand Neuron, D-neuron. Recent Developments in Medicine and Medical Research Vol. 4, 166–174. https://doi.org/10.9734/bpi/rdmmr/v4/13668D